TRPV4 and acute respiratory distress syndrome: Inhibition of TRPV4 has also been suggested to be a promising therapeutic route for treating acute lung injury/acute respiratory distress syndrome (ARDS) (Goldenberg et al., 2015a), and more recently for treating COVID-19 patients with lung edema (Kuebler et al., 2020).